TMO · Thermo Fisher Scientific Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted operating margin non-GAAP | 21.8% | Q1 call | — |
| share repurchases | $3B | Q1 call | — |
| Capital deployment | 16.5B | full year 2025 | — |
| Capital returned to shareholders through stock buybacks and dividends | 3.6B | full year 2025 | — |
| M&A capital deployment | 13B | full year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TMO
this stock
Thermo Fisher Scientific Inc.
|
$195.56B | -9.1% | +0.4% | 28.9 | 1.4% |
|
DHR
Danaher Corp /De/
|
$142.34B | -11.8% | +8.5% | 35.9 | 1.5% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.58B | -18.3% | +10.4% | 40.7 | 2.5% |
|
NTRA
Natera, Inc.
|
$38.26B | +16.6% | -2.8% | — | 4.1% |
|
A
Agilent Technologies, Inc.
|
$37.52B | -2.0% | +6.4% | 26.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TMO | -0.4% | +14.1% | -15.9% | +5.0% | -9.1% |
| SPY | -1.0% | -0.6% | +7.1% | -0.6% | +8.8% |
| vs SPY | +0.5% | +14.7% | -23.1% | +5.6% | -17.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.